Wilmington PharmaTech (WPT), a manufacturer of small molecule active pharmaceutical ingredients (API) based in Newark, Delaware, has announced that it will receive a majority investment from the Los Angeles-based private equity firm, Curewell Capital. This strategic acquisition is intended to accelerate WPT’s growth and enhance its capabilities in domestic pharmaceutical manufacturing.
Dr. Hui-Yin “Harry” Li, the founder and CEO of Wilmington PharmaTech, will retain a significant ownership stake in the company and will continue to oversee operations alongside the existing management team. The partnership is expected to provide substantial capital, enabling WPT to expand its manufacturing footprint and improve its end-to-end API development and production services.
Founded in 2003, Wilmington PharmaTech has established itself as a trusted partner for global drug developers. The company offers integrated services that encompass discovery, clinical development, and commercial-scale manufacturing. Its 54-acre campus in Delaware features two advanced facilities equipped with current Good Manufacturing Practice (cGMP) and high potency API suites, as well as a research and development center located in Suzhou, China.
Investment Aims to Meet Rising Demand
In a statement, Dr. Li expressed optimism about the future of Wilmington PharmaTech, stating, “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies. We are committed to expanding our capabilities and capacity to better serve our global biopharmaceutical partners.”
Curewell Capital partner Michael Dal Bello highlighted the scientific depth and operational excellence of Wilmington PharmaTech, noting that the investment is strategically timed with the increasing demand for specialized pharmaceutical manufacturing in the United States. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity,” Dal Bello stated.
The transaction positions Wilmington PharmaTech to capitalize on the growing domestic and international need for advanced API development. This investment not only strengthens WPT’s operational capabilities but also enhances its role as a key manufacturing partner for biopharmaceutical innovators both in the U.S. and abroad.
As the pharmaceutical industry continues to evolve, Wilmington PharmaTech’s partnership with Curewell Capital is set to provide the necessary resources to meet future challenges and demands in the ever-expanding biopharmaceutical market.
